Prostate Cancer Foundation

donate ribbon

Donate Now    FAQs   Contact Us   Español   twitter   facebook

Navigation

Research News

Fast Track Treatment Continues to Make Progress

February 7, 2012 -- On June 6, 2011, the Prostate Cancer Foundation reported promising Phase III clinical trial results for Radium-223 (Alpharadin) that were presented at the annual American Society of Clinical Oncology meeting in Chicago. The data showed the compound significantly improved overall survival in patients with castration-resistant prostate cancer that has metastasized to the bone. And, in late 2011, the treatment received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in patients with bone metastases.

The article below highlights the continued progress and success of Radium-223, presented at the Genitourinary Cancers Symposium in February 2012, by Drs. A. Oliver Sartor, Laborde Professor of Cancer Research at Tulane University, New Orleans, and medical director of the Tulane Cancer Center, and Dr. Chris Parker of the Royal Marsden NHS Foundation Trust in Sutton, England.

Read about the Work Conducted by Drs. Sartor and Parker

Read about the FDA Fast Track Designation

Read about Alpharadin

Back to Research and Therapeutics

Back to All Research News

Print | Bookmark and Share

2000 Programs Worldwide

Progress Reports

prostate cancer guides and books

prostate cancer clinical trials

patient support

athletes for a cure